Accès direct au contenu

Recherche avancée


Enseignant chercheur

M. Denis Mulleman

PROFESSEUR DES UNIV - PRATICIEN HOSP
Rhumatologie
Denis Mulleman 2 Dec 2014.JPG
Structure(s) de rattachement :
UFR de Médecine > Rhumatologie

UFR de Médecine > Génétique, Immunothérapie, Chimie et Cancer (GICC)
Courriel :
denis.mulleman@univ-tours.fr
Adresse :
Avenue de la République 37170 CHAMBRAY LES TOURS
10 Boulevard Tonnellé 37032 TOURS CEDEX 1
Adresse site personnel :
http://gicc.cnrs.univ-tours.fr/about-us/
Téléphone 2 :
+33 2 47 36 61 44

Fonction

Member of the CNRS research unit 7292 (team 1: “Antibodies, Fc receptors and clinical responses”, Head Prof. Gilles Paintaud) Representative of the team in European and international projects

Thèmes de recherche

Concentration-response relationship of monoclonal antibodies and Fc-containing fusion proteins in inflammatory rheumatic diseases

Activités / CV

Clinical studies:
  1. Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA) NCT00497614 (Principal Investigator)
  2. Pharmaco Kinetic Variability of Infliximab in Rheumatoid Arthritis (FAKIR) NCT00840957 (Principal Investigator)
  3. Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA) NCT01382160 (Principal Investigator)
  4. Combinaison of Methotrexate to Adalimumab to Reduce Immunization in ankylosing Spondylitis (CoMARIS) NCT01895764 (Co-Investigator)
  5. Relationship between T LYmphocytes depletion and clinical response to RITUXimab in rheumatoid arthritis (LYRITUX) NCT02304354 (Co-Investigator)

Key words: biopharmaceuticals, monoclonal antibodies, concentration-response relationship, modelling, therapeutic drug monitoring, immunogenicity

Informations complémentaires

Member of Le Studium® Research Consortium Monitoring of monoclonal Antibodies Groupe in Europe (MAGE) for inflammatory diseases
  • Facebook
  • twitter
  • google
  • imprimer
  • version PDF
  • Envoyer cette page

Five recent publications

1. Mulleman D, Ducourau E, Paintaud G, Ternant D, Watier H, Goupille P. Should anti-TNF-alpha drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis? Joint Bone Spine. 2012;79(2):109-12.

2. Mélet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. 2013;65(11):2783-90.

3. Ducourau E, Ternant D, Lequerre T, Fuzibet P, Le Loet X, Watier H, Goupille P, Paintaud G, Vittecoq O, Mulleman D. Towards an individualised target concentration of adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2014;73(7):1428-9.

4. Ternant D, Ducourau E, Perdriger A, Corondan A, Le Goff B, Devauchelle-Pensec V, Solau-Gervais E, Watier H, Goupille P, Paintaud G, Mulleman D. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol. 2014;78(1):118-28.

5. Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerre T, Le Loet X, Vittecoq O, Goupille P, Mulleman D, Paintaud G. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015;79(2):286-97.

Recherche dans l'annuaire

Recherche dans l'annuaire